Biopharmaceutical company Gilead Sciences Inc (Nasdaq: GILD) on Monday reported real-world results from the BICSTaR study that reinforces the use of Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a generally well tolerated and efficacious regimen regardless of prior treatment and comorbidity status in people with HIV.

This latest five-year data from two Phase 3 studies (Study 1489 and Study 1490) provides evidence of the long-term safety and efficacy profile of Biktarvy in patients who switch from a dolutegravir-containing regimen.

Gilead presented new real-world data from the 24-month BICSTaR follow-up analysis which evaluated the effectiveness and safety of Biktarvy in clinical practice across nine countries. This analysis included follow-up during the COVID-19 pandemic and considered age, race, sex, adherence and late diagnosis in the population group.

The company stated that trial participants who initiated treatment with Biktarvy experienced high viral suppression (HIV-1 RNA